Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection
about
Antiviral prevention of sepsis induced cytomegalovirus reactivation in immunocompetent mice.T-bet:Eomes balance, effector function, and proliferation of cytomegalovirus-specific CD8+ T cells during primary infection differentiates the capacity for durable immune control.Polyfunctional cytomegalovirus-specific immunity in lung transplant recipients receiving valganciclovir prophylaxis.Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease.Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients.Hyperexpansion of Functional Viral-Specific CD8+ T Cells in Lymphopenia-Associated MCMV Pneumonitis.Transient CD8-memory contraction: a potential contributor to latent cytomegalovirus reactivation.Polyfunctional T-Cell Signatures to Predict Protection from Cytomegalovirus after Lung TransplantationBroncholaveolar lavage to detect cytomegalovirus infection, latency, and reactivation in immune competent hostsEffector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.High-quality CMV-specific CD4+ memory is enriched in the lung allograft and is associated with mucosal viral controlViral infections in lung transplant recipients.Is prevention the best treatment? CMV after lung transplantation.Tissue-resident T cells, in situ immunity and transplantation.Immune-based monitoring for cytomegalovirus infection in solid organ transplantation: is it ready for clinical primetime?High CXCL-16 levels correlate with symptomatic disease in lung transplant recipients with human cytomegalovirus replication in the allograft.Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients.
P2860
Q33695591-17523696-65A1-4C13-A33F-711467C5F32CQ34550760-54F74BD6-B6F0-4D08-AAF0-40A34B4D9826Q34605186-DC483D0A-3D30-4C50-94BB-619F0EA790EEQ34987059-2D321656-48B7-4BD4-B7AD-0EA3D76EF2A3Q35463623-89C73FC9-DB4C-47B8-894B-488761DDAED1Q35801652-15BB8DE9-9797-4839-B855-DE31AD9CFB38Q36332722-DD1D1035-D7DC-4CBD-ACAD-2F7F42628A00Q36516505-F3276DC9-E7B8-4FD0-966E-CE393BEDF816Q37025600-7E663D98-1C13-4718-9C12-DC695FAAC8B7Q37287080-54C59C2E-3CF9-4982-B7B5-36ACD4207076Q37308147-8B055301-55B5-49CA-A2BC-14799C68967BQ37721885-F2F6DEFB-ADDF-45F9-AFC3-CFFDAC9D866AQ37954420-4185120E-1D79-44DE-8507-F3B0EDF39C3CQ38187175-BF364A76-6FFD-4F01-919E-158336428ED5Q38235723-656DCF92-DAF6-4095-BCDF-747C37397AA3Q42198626-8791149E-4E54-4384-AE92-EB27E7AF9631Q43909393-38C97D39-F04F-40D6-9F0B-0EAEFA69C7DC
P2860
Differential CMV-specific CD8+ effector T cell responses in the lung allograft predominate over the blood during human primary infection
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Differential CMV-specific CD8+ ...... during human primary infection
@en
Differential CMV-specific CD8+ ...... uring human primary infection.
@nl
type
label
Differential CMV-specific CD8+ ...... during human primary infection
@en
Differential CMV-specific CD8+ ...... uring human primary infection.
@nl
prefLabel
Differential CMV-specific CD8+ ...... during human primary infection
@en
Differential CMV-specific CD8+ ...... uring human primary infection.
@nl
P2093
P2860
P1476
Differential CMV-specific CD8+ ...... during human primary infection
@en
P2093
Alexandra Valsamakis
Amanda B Whitlock
Christine M Osborne
David R Moller
Erin E West
John F McDyer
Jonathan B Orens
Lesia K Dropulic
Mark Connors
Matthew H Willett
P2860
P304
P356
10.4049/JIMMUNOL.181.1.546
P407
P577
2008-07-01T00:00:00Z